The company remains entirely pre-revenue, with operating losses widening to $3.8 million in 2025Q4 due to escalating R&D and administrative expenses.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 342K | 118K | 4K | 5K | 6K | 1K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -342K | -118K | -4K | -5K | -6K | -1K |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | -189.83% | -2850% | 20% | 16.67% | -500% | - |
| Operating Expenses | 5.91M | 1.3M | 635K | 895K | 697K | 71K |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 3.77M | 768K | 303K | 548K | 452K | 33K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 2.13M | 534K | 332K | 347K | 245K | 38K |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.25M | -1.3M | -635K | -895K | -703K | -72K |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | -379.95% | -105.04% | 29.05% | -27.31% | -876.39% | - |
| EBITDA | -5.91M | -1.18M | -631K | -890K | -697K | -71K |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -398.9% | -87.64% | 29.1% | -27.69% | -881.69% | - |
| D&A (Non-Cash Add-back) | 342K | 118K | 4K | 5K | 6K | 1K |
| EBIT | -6.25M | -1.54M | -635K | -777K | -709K | -73K |
| Net Interest Income | -2.77M | -28K | -230K | -2K | -2K | 0 |
| Interest Income | 370K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.14M | 3K | 2K | 2K | 2K | 0 |
| Other Income/Expense | 2.91M | -243K | 35K | 116K | -8K | -1K |
| Pretax Income | -3.33M | -1.54M | -600K | -779K | -711K | -73K |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.33M | -1.54M | -600K | -779K | -711K | -73K |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -115.86% | -157.5% | 22.98% | -9.56% | -873.97% | - |
| Net Income (Continuing) | -3.33M | -1.54M | -600K | -779K | -711K | -73K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.07 | -134.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Growth % | 98.46% | - | - | - | - | - |
| EPS (Basic) | -2.07 | -134.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diluted Shares Outstanding | 1.61M | 11.96K | 0 | 0 | 0 | 0 |
| Basic Shares Outstanding | 1.61M | 11K | 0 | 0 | 0 | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - |
Imminent liquidity depletion risk
As indicated by the company's financial statements, Polyrizon remains entirely pre-revenue, with no top-line growth recorded across the last ten quarters, underscoring the firm's status as a speculative development-stage entity reliant on future regulatory milestones rather than current commercial market penetration or existing product sales.
The absence of revenue suggests that the company has yet to transition from a research-oriented laboratory model to a commercial enterprise. Investors should monitor the lack of top-line activity as a primary indicator that the firm's valuation remains tied exclusively to intellectual property potential rather than operational performance.
Based on reported figures, the company's cost structure has shifted significantly, with R&D expenses reaching $1.4 million and SG&A expenses hitting $2.3 million in 2025Q4, reflecting an aggressive acceleration in spending that appears disconnected from any corresponding progress in revenue generation or commercial readiness.
The sharp increase in operating expenses suggests that the company is attempting to accelerate clinical trial execution or regulatory filings. This rapid expansion of the cost base, in the absence of revenue, implies a high probability of further dilutive financing requirements in the near term.
According to recent income statement data, the firm's operating loss widened to $3.8 million in 2025Q4, demonstrating that overhead costs are scaling rapidly without the support of gross profit, which remains negative due to the persistent absence of product sales and ongoing manufacturing-related expenses.
The widening gap between operating expenses and the lack of revenue indicates a lack of operating leverage, which is typical for early-stage biotech firms. This trend suggests that the company's current business model is not yet self-sustaining and requires significant capital injections to cover basic operating requirements.
As reported in financial filings, the company's net loss of $3.2 million in 2025Q4, combined with a cash balance of approximately $1.3 million, suggests that the firm faces a critical liquidity shortfall that may necessitate immediate capital raises to avoid a potential going concern event.
Short-sellers would likely focus on the mismatch between the current cash position and the quarterly burn rate, which appears to be accelerating. This dynamic implies that the company may be forced into highly dilutive equity offerings, which would significantly impair the value for existing shareholders.
Quick answers to the most common questions about buying PLRZ stock.
For fiscal year 2025, Polyrizon Ltd. (PLRZ) reported total revenue of $0.0M.
Polyrizon Ltd. (PLRZ) reported a net loss of $3.3M for the fiscal year ending 2025.